Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on year to $7.80 billion. On the other hand, the company’s full-year revenue guidance of $30.25 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP loss of $6.75 per share was 6.9% above analysts’ consensus estimates.
Is now the time to buy Gilead Sciences? Find out by accessing our full research report, it’s free.
Gilead Sciences (GILD) Q2 CY2026 Highlights:
- Revenue: $7.80 billion vs analyst estimates of $7.35 billion (10.2% year-on-year growth, 6.2% beat)
- Adjusted EPS: -$6.75 vs analyst estimates of -$7.25 (6.9% beat)
- Adjusted Operating Income: -$7.33 billion vs analyst estimates of -$8.02 billion (-93.9% margin, 8.6% beat)
- The company slightly lifted its revenue guidance for the full year to $30.25 billion at the midpoint from $30.2 billion
- Management raised its full-year Adjusted EPS guidance to -$0.48 at the midpoint, a 44.1% increase
- Operating Margin: -133%, down from 34.9% in the same quarter last year
- Free Cash Flow Margin: 44%, up from 10.2% in the same quarter last year
- Market Capitalization: $162.8 billion
Company Overview
From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Regrettably, Gilead Sciences’s sales grew at a tepid 2.7% compounded annual growth rate over the last five years. This wasn’t a great result, but there are still things to like about Gilead Sciences.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Gilead Sciences’s annualized revenue growth of 4.7% over the last two years is above its five-year trend, which is encouraging. 
We can dig further into the company’s revenue dynamics by analyzing its most important segment, HIV. Over the last two years, Gilead Sciences’s HIV revenue averaged 3.3% year-on-year growth. This segment has lagged the company’s overall sales. 
This quarter, Gilead Sciences reported year-on-year revenue growth of 10.2%, and its $7.80 billion of revenue exceeded Wall Street’s estimates by 6.2%.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and suggests its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Gilead Sciences has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 32.5%.
Looking at the trend in its profitability, Gilead Sciences’s adjusted operating margin decreased by 34.2 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 19.5 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
In Q2, Gilead Sciences generated an adjusted operating margin profit margin of negative 93.9%, down 140.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Sadly for Gilead Sciences, its EPS declined by 15.4% annually over the last five years while its revenue grew by 2.7%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
Diving into the nuances of Gilead Sciences’s earnings can give us a better understanding of its performance. As we mentioned earlier, Gilead Sciences’s adjusted operating margin declined by 34.2 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.
In Q2, Gilead Sciences reported adjusted EPS of negative $6.75, down from $2.01 in the same quarter last year. Despite falling year on year, this print beat analysts’ estimates by 6.9%. Over the next 12 months, Wall Street is optimistic. Analysts forecast Gilead Sciences’s full-year EPS will flip from negative $0.39 to positive $8.84.
Key Takeaways from Gilead Sciences’s Q2 Results
We were impressed by how significantly Gilead Sciences blew past analysts’ revenue expectations this quarter. We were also excited its full-year EPS guidance outperformed Wall Street’s estimates by a wide margin. On the other hand, its full-year revenue guidance slightly missed. Overall, we think this was a mixed quarter. The stock remained flat at $134.30 immediately after reporting.
Gilead Sciences may have had a good quarter, but does that mean you should invest right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).